Zentalis Pharmaceuticals granted non-qualified stock options covering 269,000 common shares to four newly hired employees under its 2022 inducement plan.
Options were priced at $3.71 per share, matching the Nasdaq closing price on the grant date.
Award term runs 10 years; vesting spans four years with 25% after year one, then monthly vesting over three years.
ZNTL•
